Update shared on 28 Aug 2025
With both Tarsus Pharmaceuticals’ future P/E ratio (19.91x) and net profit margin (27.99%) remaining stable, there is no shift in analyst sentiment or valuation, and the consensus analyst price target is unchanged at $76.00.
What's in the News
- Dropped from Russell Microcap Growth Benchmark Index
- Dropped from Russell 3000E Growth Benchmark
- Dropped from Russell 3000E Index
- Dropped from Russell Microcap Index
- Dropped from Russell 3000E Growth Index
Valuation Changes
Summary of Valuation Changes for Tarsus Pharmaceuticals
- The Consensus Analyst Price Target remained effectively unchanged, at $76.00.
- The Future P/E for Tarsus Pharmaceuticals remained effectively unchanged, at 19.91x.
- The Net Profit Margin for Tarsus Pharmaceuticals remained effectively unchanged, at 27.99%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.